CoChat

Enhancers Are Major Targets for Murine Leukemia Virus Vector Integration

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Retroviral vectors have been used in successful gene therapies. However, in some patients, insertional mutagenesis led to leukemia or myelodysplasia. Both the strong promoter/enhancer elements in the long terminal repeats (LTRs) of murine leukemia virus (MLV)-based vectors and the vector-specific integration site preferences played an important role in these adverse clinical events. MLV integration is known to prefer regions in or near transcription start sites (TSS). Recently, BET family proteins were shown to be the major cellular proteins responsible for targeting MLV integration. Although MLV integration sites are significantly enriched at TSS, only a small fraction of the MLV integration sites (<15%) occur in this region. To resolve this apparent discrepancy, we created a high-resolution genome-wide integration map of more than one million integration sites from CD34 + hematopoietic stem cells transduced with a clinically relevant MLV-based vector. The integration sites form ∼60,000 tight clusters. These clusters comprise ∼1.9% of the genome. The vast majority (87%) of the integration sites are located within histone H3K4me1 islands, a hallmark of enhancers. The majority of these clusters also have H3K27ac histone modifications, which mark active enhancers. The enhancers of some oncogenes, including LMO2, are highly preferred targets for integration without in vivo selection. IMPORTANCE We show that active enhancer regions are the major targets for MLV integration; this means that MLV preferentially integrates in regions that are favorable for viral gene expression in a variety of cell types. The results provide insights for MLV integration target site selection and also explain the high risk of insertional mutagenesis that is associated with gene therapy trials using MLV vectors.

Overview

Integrity signals

Registry

Crossref · 10.1128/jvi.00011-14

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Cited by

See all 104

Metadata

Authors
De Ravin, S. S., Su, L., Theobald, N., Choi, U., Macpherson, J. L., Poidinger, M., Symonds, G., Pond, S. M., Ferris, A. L., Hughes, S. H., Malech, H. L., & Wu, X.
Affiliations
  • Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
  • Frederick National Laboratory for Cancer Research (US)
  • National Institutes of Health (US)
  • Johnson & Johnson (Australia) (AU)
  • National Cancer Institute (US)
Venue
Journal of Virology
Published
2014-04-15
Volume
88
Issue
8
Pages
4504-4513
ISSN
  • 0022-538X (ISSN-L)
  • 1098-5514
OpenAlex
W2124860395
Cited by
103
References
36
Citations by year
2025: 2 · 2024: 7 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 9 · 2017: 13 · 2016: 19 · 2015: 7 · 2014: 8
FWCI
10.26
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Journal of Virology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (HHSN261200800001C)
  • Baxter Healthcare Corporation
  • National Cancer Institute (HHSN261200800001E))
  • National Institute of Allergy and Infectious Diseases (Z01AI000644)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Health Sciences › Medicine › Surgery › Xenotransplantation and immune response
Keywords
murine leukemia virus, retroviral integration, enhancers, insertional mutagenesis, long terminal repeat, BET proteins, H3K27ac, hematopoietic stem cells, integration site mapping, LMO2, gene therapy safety
MeSH terms
Animals, Cells, Cultured, Enhancer Elements, Genetic, Genetic Vectors, Hematopoietic Stem Cells, Histones, Humans, Leukemia Virus, Murine, Genetic Therapy, Genome, Human, Mutagenesis, Insertional, Virus Integration, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhancers Are Major Targets for Murine Leukemia Virus Vector Integration. https://app.cochat.ai/papers/10.1128/jvi.00011-14
The paper
De Ravin, S. S., Su, L., Theobald, N., Choi, U., Macpherson, J. L., Poidinger, M., Symonds, G., Pond, S. M., Ferris, A. L., Hughes, S. H., Malech, H. L., & Wu, X. (2014). Enhancers Are Major Targets for Murine Leukemia Virus Vector Integration. Journal of Virology. https://doi.org/10.1128/jvi.00011-14

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.